Community-acquired pneumonia: antibiotic therapy approach after the COVID-19 pandemic. A review
Pneumonia is clearly differentiated from other focal inflammatory lung diseases of non-infectious origin. A patient with community-acquired pneumonia (CAP) should receive antibacterial drugs no later than 4 hours after the diagnosis. Initial antibacterial therapy in CAP should be based on factors af...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ZAO "Consilium Medicum"
2023-09-01
|
| Series: | Consilium Medicum |
| Subjects: | |
| Online Access: | https://consilium.orscience.ru/2075-1753/article/viewFile/609535/138175 |
| _version_ | 1797261565986078720 |
|---|---|
| author | Andrey A. Zaytsev Igor A. Guchev |
| author_facet | Andrey A. Zaytsev Igor A. Guchev |
| author_sort | Andrey A. Zaytsev |
| collection | DOAJ |
| description | Pneumonia is clearly differentiated from other focal inflammatory lung diseases of non-infectious origin. A patient with community-acquired pneumonia (CAP) should receive antibacterial drugs no later than 4 hours after the diagnosis. Initial antibacterial therapy in CAP should be based on factors affecting the potential causative agents and the risk of drug-resistant microorganisms. Rational use of amoxicillin in terms of dose and frequency in CAP patients without severe comorbidities and risk factors for PES pathogens, the use of -lactam in combination with a macrolide or moxifloxacin monotherapy in high-risk groups of patients is the most effective strategy of empirical antibacterial therapy. |
| first_indexed | 2024-04-24T23:43:15Z |
| format | Article |
| id | doaj.art-622bcb11217c4bb0bad60075e1e258d9 |
| institution | Directory Open Access Journal |
| issn | 2075-1753 2542-2170 |
| language | Russian |
| last_indexed | 2024-04-24T23:43:15Z |
| publishDate | 2023-09-01 |
| publisher | ZAO "Consilium Medicum" |
| record_format | Article |
| series | Consilium Medicum |
| spelling | doaj.art-622bcb11217c4bb0bad60075e1e258d92024-03-15T09:57:58ZrusZAO "Consilium Medicum"Consilium Medicum2075-17532542-21702023-09-0125958158810.26442/20751753.2023.9.2024084722Community-acquired pneumonia: antibiotic therapy approach after the COVID-19 pandemic. A reviewAndrey A. Zaytsev0https://orcid.org/0000-0002-0934-7313Igor A. Guchev1Burdenko Main Military Clinical HospitalNikita and Co LLCPneumonia is clearly differentiated from other focal inflammatory lung diseases of non-infectious origin. A patient with community-acquired pneumonia (CAP) should receive antibacterial drugs no later than 4 hours after the diagnosis. Initial antibacterial therapy in CAP should be based on factors affecting the potential causative agents and the risk of drug-resistant microorganisms. Rational use of amoxicillin in terms of dose and frequency in CAP patients without severe comorbidities and risk factors for PES pathogens, the use of -lactam in combination with a macrolide or moxifloxacin monotherapy in high-risk groups of patients is the most effective strategy of empirical antibacterial therapy.https://consilium.orscience.ru/2075-1753/article/viewFile/609535/138175pneumoniamoxifloxacinmacrolidescovid-19 |
| spellingShingle | Andrey A. Zaytsev Igor A. Guchev Community-acquired pneumonia: antibiotic therapy approach after the COVID-19 pandemic. A review Consilium Medicum pneumonia moxifloxacin macrolides covid-19 |
| title | Community-acquired pneumonia: antibiotic therapy approach after the COVID-19 pandemic. A review |
| title_full | Community-acquired pneumonia: antibiotic therapy approach after the COVID-19 pandemic. A review |
| title_fullStr | Community-acquired pneumonia: antibiotic therapy approach after the COVID-19 pandemic. A review |
| title_full_unstemmed | Community-acquired pneumonia: antibiotic therapy approach after the COVID-19 pandemic. A review |
| title_short | Community-acquired pneumonia: antibiotic therapy approach after the COVID-19 pandemic. A review |
| title_sort | community acquired pneumonia antibiotic therapy approach after the covid 19 pandemic a review |
| topic | pneumonia moxifloxacin macrolides covid-19 |
| url | https://consilium.orscience.ru/2075-1753/article/viewFile/609535/138175 |
| work_keys_str_mv | AT andreyazaytsev communityacquiredpneumoniaantibiotictherapyapproachafterthecovid19pandemicareview AT igoraguchev communityacquiredpneumoniaantibiotictherapyapproachafterthecovid19pandemicareview |